Long‐term outcome of immunologic autograft engineering

Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still...

Descripción completa

Detalles Bibliográficos
Autores principales: Porrata, Luis F., Inwards, David J., Ansell, Stephen M., Micallef, Ivana N., Johnston, Patrick B., Villasboas, Jose C., Paludo, Jonas, Markovic, Svetomir N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176079/
https://www.ncbi.nlm.nih.gov/pubmed/35846064
http://dx.doi.org/10.1002/jha2.404
_version_ 1784722584811601920
author Porrata, Luis F.
Inwards, David J.
Ansell, Stephen M.
Micallef, Ivana N.
Johnston, Patrick B.
Villasboas, Jose C.
Paludo, Jonas
Markovic, Svetomir N.
author_facet Porrata, Luis F.
Inwards, David J.
Ansell, Stephen M.
Micallef, Ivana N.
Johnston, Patrick B.
Villasboas, Jose C.
Paludo, Jonas
Markovic, Svetomir N.
author_sort Porrata, Luis F.
collection PubMed
description Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still confers survival benefit with a longer follow‐up. With a median follow‐up of 127.6 months, patients infused with an A‐ALC ≥ 0.5 × 10(9) cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224–0.687, p < 0.001) and progression‐free survival (HR = 0.413, 95% CI: 0.253–0.677), p < 0.0004). This study supports that A‐ALC provides long‐term survival benefit post APBHSCT.
format Online
Article
Text
id pubmed-9176079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91760792022-07-14 Long‐term outcome of immunologic autograft engineering Porrata, Luis F. Inwards, David J. Ansell, Stephen M. Micallef, Ivana N. Johnston, Patrick B. Villasboas, Jose C. Paludo, Jonas Markovic, Svetomir N. EJHaem Short Reports Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still confers survival benefit with a longer follow‐up. With a median follow‐up of 127.6 months, patients infused with an A‐ALC ≥ 0.5 × 10(9) cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224–0.687, p < 0.001) and progression‐free survival (HR = 0.413, 95% CI: 0.253–0.677), p < 0.0004). This study supports that A‐ALC provides long‐term survival benefit post APBHSCT. John Wiley and Sons Inc. 2022-02-24 /pmc/articles/PMC9176079/ /pubmed/35846064 http://dx.doi.org/10.1002/jha2.404 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Porrata, Luis F.
Inwards, David J.
Ansell, Stephen M.
Micallef, Ivana N.
Johnston, Patrick B.
Villasboas, Jose C.
Paludo, Jonas
Markovic, Svetomir N.
Long‐term outcome of immunologic autograft engineering
title Long‐term outcome of immunologic autograft engineering
title_full Long‐term outcome of immunologic autograft engineering
title_fullStr Long‐term outcome of immunologic autograft engineering
title_full_unstemmed Long‐term outcome of immunologic autograft engineering
title_short Long‐term outcome of immunologic autograft engineering
title_sort long‐term outcome of immunologic autograft engineering
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176079/
https://www.ncbi.nlm.nih.gov/pubmed/35846064
http://dx.doi.org/10.1002/jha2.404
work_keys_str_mv AT porrataluisf longtermoutcomeofimmunologicautograftengineering
AT inwardsdavidj longtermoutcomeofimmunologicautograftengineering
AT ansellstephenm longtermoutcomeofimmunologicautograftengineering
AT micallefivanan longtermoutcomeofimmunologicautograftengineering
AT johnstonpatrickb longtermoutcomeofimmunologicautograftengineering
AT villasboasjosec longtermoutcomeofimmunologicautograftengineering
AT paludojonas longtermoutcomeofimmunologicautograftengineering
AT markovicsvetomirn longtermoutcomeofimmunologicautograftengineering

Ejemplares similares